Cargando...
Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
Abl1 kinase has important biological roles. The Bcr-Abl1 fusion protein creates undesired kinase activity and is pathogenic in 95% of chronic myeloid leukemia (CML) and 30% of acute lymphoblastic leukemia (ALL) patients. Targeted therapies to these diseases are tyrosine kinase inhibitors. The extent...
Guardado en:
| Publicado en: | Int J Mol Sci |
|---|---|
| Autores principales: | , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
MDPI
2020
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7555546/ https://ncbi.nlm.nih.gov/pubmed/32911643 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms21186556 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|